News

2021 - 2022

  • Categories:History
  • Author:
  • Origin:
  • Time of issue:2023-11-13
  • Views:0

(Summary description)<h3 style="font-size:20px; font-weight:bold;">beholding the sun blazing forth from a cloudy sky
</h3>
◆ Shenggliptin, a new hypoglycemic drug, completed Phase III clinical trials
◆ The first domestically produced rare disease drug approved for launch
◆ Four new anti-tumor drugs have been approved for clinical use, and two Sino US dual reports
◆ Awarded as a major innovation team in Suzhou

2021 - 2022

(Summary description)<h3 style="font-size:20px; font-weight:bold;">beholding the sun blazing forth from a cloudy sky
</h3>
◆ Shenggliptin, a new hypoglycemic drug, completed Phase III clinical trials
◆ The first domestically produced rare disease drug approved for launch
◆ Four new anti-tumor drugs have been approved for clinical use, and two Sino US dual reports
◆ Awarded as a major innovation team in Suzhou

  • Categories:History
  • Author:
  • Origin:
  • Time of issue:2023-11-13
  • Views:0

beholding the sun blazing forth from a cloudy sky

Previous: /
Previous: /
Brainstorming

Brainstorming | Exploring the Ocean of Stars through Metabolism

With the advancement of the Healthy China 2030 Plan, chronic disease drugs have become a focus of pharmaceutical research and development. Among them, the development of cardiovascular, lipid-lowering, and hypoglycemic and weight loss drugs has become a hot track in the industry. Recently, R&D clients and Haomai Technology held a "brainstorming session" in Zhuhai, focusing on clinical needs, industry trends, and the latest drug development trends in the field of metabolic diseases. Dr. Yu Qiang, founder and CEO of Shengshi Taike, attended the conference and explored the vast universe of chronic disease drugs with guests starting from metabolism.
2024-05-28
Shengshi

Shengshi Taike has once again been listed on the "Top 50 Most Influential Medical and Health Enterprises in China" list

Recently, CHC Medical Consulting and CITIC Securities officially released the "2023 China Healthcare Industry Investment and Financing Honor List". As an innovative pharmaceutical company in the commercialization stage, Shengshi Taike has once again been listed in this category and won the honor of being one of the top 50 most influential medical and health enterprises in China in 2023.
2024-05-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO